Literature DB >> 18334608

Myostatin, activin receptor IIb, and follistatin-like-3 gene expression are altered in adipose tissue and skeletal muscle of obese mice.

David L Allen1, Allison S Cleary, Kristin J Speaker, Sarah F Lindsay, Jill Uyenishi, Jason M Reed, Molly C Madden, Ryan S Mehan.   

Abstract

Myostatin (MSTN) is a secreted growth inhibitor expressed in muscle and adipose. We sought to determine whether expression of MSTN, its receptor activin RIIb (ActRIIb), or its binding protein follistatin-like-3 (FSTL3) are altered in subcutaneous or visceral adipose or in skeletal muscle in response to obesity. MSTN and ActRIIb mRNA levels were low in subcutaneous (SQF) and visceral fat (VF) from wild-type mice but were 50- to 100-fold higher in both SQF and VF from ob/ob compared with wild-type mice. FSTL3 mRNA levels were increased in SQF but decreased in VF in ob/ob compared with wild-type mice. Moreover, MSTN mRNA levels were twofold greater in tibialis anterior (TA) from ob/ob mice, whereas ActRIIb and FSTL3 mRNA levels were unchanged. MSTN mRNA levels were also increased in TA and SQF from mice on a high-fat diet. Injection of ob/ob mice with recombinant leptin caused FSTL3 mRNA levels to decrease in both VF and SQF in ob/ob mice; MSTN and ActRIIb mRNA levels tended to decrease only in VF. Finally, MSTN mRNA levels and promoter activity were low in adipogenic 3T3-L1 cells, but an MSTN promoter-reporter construct was activated in 3T3-L1 cells by cotransfection with the adipogenic transcription factors SREBP-1c, C/EBPalpha, and PPARgamma. These results demonstrate that expression of MSTN and its associated binding proteins can be modulated in adipose tissue and skeletal muscle by chronic obesity and suggest that alterations in their expression may contribute to the changes in growth and metabolism of lean and fat tissues occurring during obesity.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18334608     DOI: 10.1152/ajpendo.00798.2007

Source DB:  PubMed          Journal:  Am J Physiol Endocrinol Metab        ISSN: 0193-1849            Impact factor:   4.310


  82 in total

Review 1.  Muscles, exercise and obesity: skeletal muscle as a secretory organ.

Authors:  Bente K Pedersen; Mark A Febbraio
Journal:  Nat Rev Endocrinol       Date:  2012-04-03       Impact factor: 43.330

2.  METABOLIC FUNCTIONS OF MYOSTATIN AND GDF11.

Authors:  Alexandra C McPherron
Journal:  Immunol Endocr Metab Agents Med Chem       Date:  2010-12

3.  Fighting obesity: When muscle meets fat.

Authors:  Xin Yang; Pengpeng Bi; Shihuan Kuang
Journal:  Adipocyte       Date:  2014-12-10       Impact factor: 4.534

4.  Myostatin induces insulin resistance via Casitas B-lineage lymphoma b (Cblb)-mediated degradation of insulin receptor substrate 1 (IRS1) protein in response to high calorie diet intake.

Authors:  Sabeera Bonala; Sudarsanareddy Lokireddy; Craig McFarlane; Sreekanth Patnam; Mridula Sharma; Ravi Kambadur
Journal:  J Biol Chem       Date:  2014-01-22       Impact factor: 5.157

5.  Myostatin directly regulates skeletal muscle fibrosis.

Authors:  Zhao Bo Li; Helen D Kollias; Kathryn R Wagner
Journal:  J Biol Chem       Date:  2008-05-03       Impact factor: 5.157

6.  Calcineurin activates interleukin-6 transcription in mouse skeletal muscle in vivo and in C2C12 myotubes in vitro.

Authors:  David L Allen; Jill J Uyenishi; Allison S Cleary; Ryan S Mehan; Sarah F Lindsay; Jason M Reed
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2009-11-11       Impact factor: 3.619

7.  The correlation of resistance exercise-induced myostatin with insulin resistance and plasma cytokines in healthy young men.

Authors:  F Kazemi
Journal:  J Endocrinol Invest       Date:  2015-08-18       Impact factor: 4.256

8.  Myostatin inhibition in muscle, but not adipose tissue, decreases fat mass and improves insulin sensitivity.

Authors:  Tingqing Guo; William Jou; Tatyana Chanturiya; Jennifer Portas; Oksana Gavrilova; Alexandra C McPherron
Journal:  PLoS One       Date:  2009-03-19       Impact factor: 3.240

9.  Activin signaling as an emerging target for therapeutic interventions.

Authors:  Kunihiro Tsuchida; Masashi Nakatani; Keisuke Hitachi; Akiyoshi Uezumi; Yoshihide Sunada; Hiroshi Ageta; Kaoru Inokuchi
Journal:  Cell Commun Signal       Date:  2009-06-18       Impact factor: 5.712

10.  Leptin administration favors muscle mass accretion by decreasing FoxO3a and increasing PGC-1alpha in ob/ob mice.

Authors:  Neira Sáinz; Amaia Rodríguez; Victoria Catalán; Sara Becerril; Beatriz Ramírez; Javier Gómez-Ambrosi; Gema Frühbeck
Journal:  PLoS One       Date:  2009-09-04       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.